- Home
- ATHA vs SGBX Comparison
ATHA vs SGBX Comparison
Compare ATHA & SGBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SGBX
- Stock Information
- Founded
- ATHA 2011
- SGBX 2007
- Country
- ATHA United States
- SGBX United States
- Employees
- ATHA N/A
- SGBX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SGBX RETAIL: Building Materials
- Sector
- ATHA Health Care
- SGBX Consumer Discretionary
- Exchange
- ATHA Nasdaq
- SGBX Nasdaq
- Market Cap
- ATHA 18.2M
- SGBX 18.1M
- IPO Year
- ATHA 2020
- SGBX 2017
- Fundamental
- Price
- ATHA $4.72
- SGBX $3.85
- Analyst Decision
- ATHA
- SGBX
- Analyst Count
- ATHA 0
- SGBX 0
- Target Price
- ATHA N/A
- SGBX N/A
- AVG Volume (30 Days)
- ATHA 25.6K
- SGBX 18.0M
- Earning Date
- ATHA 11-06-2025
- SGBX 11-14-2025
- Dividend Yield
- ATHA N/A
- SGBX N/A
- EPS Growth
- ATHA N/A
- SGBX N/A
- EPS
- ATHA N/A
- SGBX N/A
- Revenue
- ATHA N/A
- SGBX $3,382,896.00
- Revenue This Year
- ATHA N/A
- SGBX $1,628.82
- Revenue Next Year
- ATHA N/A
- SGBX N/A
- P/E Ratio
- ATHA N/A
- SGBX N/A
- Revenue Growth
- ATHA N/A
- SGBX N/A
- 52 Week Low
- ATHA $2.20
- SGBX $1.81
- 52 Week High
- ATHA $6.79
- SGBX $122.88
- Technical
- Relative Strength Index (RSI)
- ATHA 61.31
- SGBX 53.70
- Support Level
- ATHA $4.31
- SGBX $2.72
- Resistance Level
- ATHA $4.95
- SGBX $9.34
- Average True Range (ATR)
- ATHA 0.37
- SGBX 1.36
- MACD
- ATHA -0.04
- SGBX 0.17
- Stochastic Oscillator
- ATHA 73.60
- SGBX 26.74
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.